AbbVie stock: Barclays raises price target to USD 335
Published on 11/17/2026 at 15:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and market context
- Barclays kept its Overweight rating after AbbVie's third-quarter report.
- The higher target reflects a fresh sell-side assessment as investors weigh pipeline execution.
- AbbVie stock traded below the prior Xetra close on Tuesday afternoon.
Barclays raised its AbbVie price target to USD 335 from USD 325 on Monday, November 16, while keeping an Overweight rating on the shares, Markets Insider reported. Analyst Emily Field cited AbbVie's derisked earnings profile in the research note.
Barclays lifts its target
The revised target gives investors a higher sell-side reference after AbbVie's third-quarter report. Barclays' rating remained positive, while the company continues to face execution demands across its medicines portfolio and development pipeline.
Tuesday trading remains weaker
AbbVie stock traded at 266.75 euros on Lang & Schwarz at 15:37 CET on Tuesday, November 17, 2026, 1.35 percent below the Xetra close of Monday, November 16. The European quote and the Barclays target are expressed in different currencies and refer to different trading venues.
AbbVie Inc. market details
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Home exchange: NYSE
- Lang & Schwarz quote: 266.75 euros at 15:37 CET on November 17, 2026
- Xetra close: 270.40 euros on November 16, 2026
Broader market developments remain in focus alongside healthcare shares. See Current market reports.
More company developments and market analysis are available in More news and analyses on AbbVie stock.
